抄録
The therapeutic effects of IPD-1151 T, a new anti-allergic agent, were compared with those of Tranilast in 356 patients with allergic rhinitis. The daily dosage was 300 mg (one capsule each, t.i.d.) for IPD-1151 T and 300 mg (one capsule each, t.i.d.) for Tranilast. Both test drugs were orally given for 6 weeks.
The results of this study are summarized as follows :
(1) IPD-1151 T showed significant superiority to Tranilast in “final global improvement rating”. Improvement rating was 55.0% for IPD-1151 T and 37.8% for Tranilast in terms of “moderate” plus “marked” improvement category.
(2) The item evaluated, “overall safety rating” showed significant superiority of IPD-1151 T to Tranilast. The incidence of an adverse reaction or abnormal laboratory finding was noted as 3.7% fo IPD-1151 T and 11.0% of Tranilast.
(3) The item evaluated, “global utility rating” showed significant superiority of IPD-1151 T to Tranilast. The utility rating was calculated as 53.2% of IPD-1151 T and 34.7% of Tranilast in terms of “moderately” plus “markedly” useful category.
(4) Side effects were observed in 6 patients (3.7%) of IPD-1151 T and 18 patients (11.0%) Tranilast. All of these symptoms disappeared by symptomatic treatment or discontinued test drug.
All the above results indicate that IPD-1151 T is safer and more effective than Tranilast. Therefore, IPD-1151 T is judged as a highly useful anti-allergic agent for the treatment of allergic rhinitis.
